Generics companies get green light for Lundbeck drug
The patent for Lundbeck's drug Northera has officially expired in the US, and no less than 12 companies have so far received approval from the US health authorities to market a generic version of the drug.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
On Feb. 18, the patent for Lundbeck's Northera officially expired in the US, after which companies are lining up to bite into the market, which the Danish pharmaceutical giant has exclusive rights to up until now.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck hunts for new success drugs in niche diseases
For subscribers
